Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Hydrochlorothiazide

FDA-approved product (tablet, oral), marketed as Esidrix, Hydro-D, Hydrochlorothiazide and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Hydrochlorothiazide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Angina pectoris
  • Cardiovascular disease
  • Chronic kidney disease
  • Cirrhosis of liver
  • Congestive heart failure
  • Edema
  • Glomerulonephritis
  • Heart failure
  • Hypertension
  • Myocardial infarction
  • Nephrotic syndrome
  • Preeclampsia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Thiazides, plain; Thiazides, combinations with other drugs
FDA pharmacologic class
Thiazide Diuretic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli29.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae12.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis70.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Hydrochlorothiazide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Hydrochlorothiazide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions

    NCT01149486 · start 2004-01

    Registered record
    Registry ID
    NCT01149486
    Conditions
    Healthy
    Interventions
    Losartan potassium/Hydrochlorothiazide; Hyzaar®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2004-01
    Completion
    2004-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionLosartan potassium/Hydrochlorothiazide; Hyzaar®
    PhasePhase 1
    Registry statusCompleted

  • Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

    NCT02262637 · start 2003-09

    Registered record
    Registry ID
    NCT02262637
    Conditions
    Hypertension
    Interventions
    Micardis®; MicardisPlus®
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-09
    Completion
    Not recorded
    Enrolment
    4,814

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionMicardis®; MicardisPlus®
    PhaseNot recorded
    Registry statusCompleted

  • Factorial Study of Metoprolol Succinate TOPROL-XL (324A)

    NCT00642096 · start 2003-06

    Registered record
    Registry ID
    NCT00642096
    Conditions
    High Blood Pressure (Hypertension).
    Interventions
    Metoprolol Succinate; Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-06
    Completion
    2004-07
    Enrolment
    1,900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHigh Blood Pressure (Hypertension).
    InterventionMetoprolol Succinate; Hydrochlorothiazide
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study of Fosinopril Sodium/ Hydrochlorothiazide 20/ 12.5 mg Tablets Under Fasting Conditions

    NCT00777972 · start 2003-03

    Registered record
    Registry ID
    NCT00777972
    Conditions
    Healthy
    Interventions
    Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-03
    Completion
    2003-04
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionFosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets
    PhaseNot applicable
    Registry statusCompleted

  • Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients

    NCT02172586 · start 2000-01

    Registered record
    Registry ID
    NCT02172586
    Conditions
    Hypertension
    Interventions
    Telmisartan; Losartan; Hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2000-01
    Completion
    Not recorded
    Enrolment
    363

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionTelmisartan; Losartan; Hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted